- Home
- ECX vs BCYC Comparison
ECX vs BCYC Comparison
Compare ECX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- BCYC
- Stock Information
- Founded
- ECX 2017
- BCYC 2009
- Country
- ECX China
- BCYC United Kingdom
- Employees
- ECX N/A
- BCYC N/A
- Industry
- ECX EDP Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- BCYC Health Care
- Exchange
- ECX Nasdaq
- BCYC Nasdaq
- Market Cap
- ECX 674.7M
- BCYC 565.5M
- IPO Year
- ECX N/A
- BCYC 2019
- Fundamental
- Price
- ECX $2.30
- BCYC $7.90
- Analyst Decision
- ECX Strong Buy
- BCYC Buy
- Analyst Count
- ECX 1
- BCYC 11
- Target Price
- ECX $3.20
- BCYC $22.91
- AVG Volume (30 Days)
- ECX 2.6M
- BCYC 316.1K
- Earning Date
- ECX 11-03-2025
- BCYC 10-31-2025
- Dividend Yield
- ECX N/A
- BCYC N/A
- EPS Growth
- ECX N/A
- BCYC N/A
- EPS
- ECX N/A
- BCYC N/A
- Revenue
- ECX $756,543,682.00
- BCYC $19,281,000.00
- Revenue This Year
- ECX $817.95
- BCYC N/A
- Revenue Next Year
- ECX $29.45
- BCYC N/A
- P/E Ratio
- ECX N/A
- BCYC N/A
- Revenue Growth
- ECX 3.49
- BCYC N/A
- 52 Week Low
- ECX $0.76
- BCYC $6.10
- 52 Week High
- ECX $3.25
- BCYC $25.77
- Technical
- Relative Strength Index (RSI)
- ECX 57.72
- BCYC 49.34
- Support Level
- ECX $1.98
- BCYC $7.65
- Resistance Level
- ECX $2.48
- BCYC $8.42
- Average True Range (ATR)
- ECX 0.19
- BCYC 0.51
- MACD
- ECX -0.00
- BCYC -0.08
- Stochastic Oscillator
- ECX 67.00
- BCYC 17.50
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.